GlaxoSmithKline plc’s latest addition to its immuno-oncology clinical portfolio is an anti-CD96 antibody, GSK6097608, developed in its collaboration with 23andMe, Inc.., which has just entered Phase I studies, according to the company’s chief scientific officer Hal Barron.
CD96 is an immune checkpoint protein expressed on T cells and NK cells, and blocking its effect, a new mechanism-of-action,...






